[{"id":"5e15875a-b705-45d9-82c2-48412b14a477","acronym":"","url":"https://clinicaltrials.gov/study/NCT04798781","created_at":"2021-03-15T15:53:52.732Z","updated_at":"2024-07-02T16:35:15.900Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma","source_id_and_acronym":"NCT04798781","lead_sponsor":"Andrew Hendifar, MD","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 02/14/2024","primary_completion_date":" 02/14/2024","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2024-03-07"},{"id":"d9f73772-0eed-448c-90c4-6955909f5536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03817411","created_at":"2021-01-18T18:51:40.163Z","updated_at":"2024-07-02T16:36:59.889Z","phase":"Phase 2","brief_title":"Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer","source_id_and_acronym":"NCT03817411","lead_sponsor":"Taizhou EOC Pharma Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • telatinib (BAY 57- 9352)"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 03/30/2020","primary_completion_date":" 03/30/2020","study_txt":" Completion: 01/25/2021","study_completion_date":" 01/25/2021","last_update_posted":"2019-05-07"}]